$DMAC
DiaMedica Therapeutics Inc.

2019 Q2 Form 10-Q Financial Statement

#000143774919009677 Filed on May 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $870.0K $810.0K $520.0K
YoY Change -18.69% 55.77% 271.43%
% of Gross Profit
Research & Development $1.874M $2.607M $791.0K
YoY Change 75.14% 229.58% -31.81%
% of Gross Profit
Depreciation & Amortization $0.00 $6.000K $4.000K
YoY Change -100.0% 50.0%
% of Gross Profit
Operating Expenses $1.874M $3.421M $1.306M
YoY Change 75.14% 161.94% 1.24%
Operating Profit -$2.741M -$3.421M -$1.306M
YoY Change 48.16% 161.94%
Interest Expense $0.00 $0.00 -$40.00K
YoY Change -100.0% -100.0% 300.0%
% of Operating Profit
Other Income/Expense, Net -$280.0K -$178.0K $657.0K
YoY Change -313.74% -127.09%
Pretax Income -$2.461M -$3.243M -$649.0K
YoY Change 43.16% 399.69% -50.08%
Income Tax $8.000K $9.000K $1.000K
% Of Pretax Income
Net Earnings -$2.469M -$3.252M -$650.0K
YoY Change 42.31% 400.31% -50.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$206.2K -$271.7K -$99.24K
COMMON SHARES
Basic Shares Outstanding 11.96M 11.96M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.97M $13.76M $6.720M
YoY Change 93.89% 104.75% 614.89%
Cash & Equivalents $2.974M $2.759M $6.710M
Short-Term Investments $8.000M $11.00M
Other Short-Term Assets $200.0K $300.0K $50.00K
YoY Change 81.82% 500.0% 0.0%
Inventory
Prepaid Expenses
Receivables $1.112M $929.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.28M $14.94M $7.570M
YoY Change 102.57% 97.41% 620.95%
LONG-TERM ASSETS
Property, Plant & Equipment $73.00K $90.00K $70.00K
YoY Change 4.29% 28.57% 250.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K $270.0K $270.0K
YoY Change 3.85% 0.0%
Total Long-Term Assets $521.0K $550.0K $330.0K
YoY Change 57.88% 66.67% 1550.0%
TOTAL ASSETS
Total Short-Term Assets $12.28M $14.94M $7.570M
Total Long-Term Assets $521.0K $550.0K $330.0K
Total Assets $12.80M $15.49M $7.900M
YoY Change 100.27% 96.13% 638.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $262.0K $685.0K $640.0K
YoY Change -55.59% 7.03% -39.62%
Accrued Expenses $630.0K $686.0K $410.0K
YoY Change 70.27% 67.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K
YoY Change
Total Short-Term Liabilities $947.0K $1.425M $1.110M
YoY Change -23.63% 28.38% 4.72%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $20.00K $0.00
YoY Change
Other Long-Term Liabilities $130.0K $150.0K $2.060M
YoY Change -96.47% -92.72%
Total Long-Term Liabilities $148.0K $163.0K $2.060M
YoY Change -95.98% -92.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $947.0K $1.425M $1.110M
Total Long-Term Liabilities $148.0K $163.0K $2.060M
Total Liabilities $1.095M $1.588M $3.170M
YoY Change -77.74% -49.91% 199.06%
SHAREHOLDERS EQUITY
Retained Earnings -$51.69M -$49.22M
YoY Change
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.70M $13.91M $6.748M
YoY Change
Total Liabilities & Shareholders Equity $12.80M $15.49M $7.900M
YoY Change 100.27% 96.13% 638.32%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$2.469M -$3.252M -$650.0K
YoY Change 42.31% 400.31% -50.38%
Depreciation, Depletion And Amortization $0.00 $6.000K $4.000K
YoY Change -100.0% 50.0%
Cash From Operating Activities -$2.880M -$3.134M -$935.0K
YoY Change 182.35% 235.19% 14.02%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $32.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $3.010M -$10.93M $0.00
YoY Change
Cash From Investing Activities $3.010M -$10.93M -$32.00K
YoY Change -30200.0% 34050.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K -2.000K 6.324M
YoY Change 40.0% -100.03% 63140.0%
NET CHANGE
Cash From Operating Activities -2.880M -3.134M -935.0K
Cash From Investing Activities 3.010M -10.93M -32.00K
Cash From Financing Activities 70.00K -2.000K 6.324M
Net Change In Cash 200.0K -14.06M 5.357M
YoY Change -120.41% -362.54% -761.36%
FREE CASH FLOW
Cash From Operating Activities -$2.880M -$3.134M -$935.0K
Capital Expenditures $0.00 $32.00K
Free Cash Flow -$2.880M -$3.134M -$967.0K
YoY Change 185.15% 224.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
18000
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11956874
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
255000
CY2018Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
292000
CY2019Q1 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
33000
CY2018Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
65000
CY2019Q1 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
33000
CY2018Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
34000
CY2019Q1 dmac Advances To Vendor
AdvancesToVendor
271000
CY2018Q4 dmac Advances To Vendor
AdvancesToVendor
271000
CY2019Q1 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
174000
CY2018Q1 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
731000
CY2019Q1 dmac Noncash Lease Expense
NoncashLeaseExpense
12000
CY2018Q1 dmac Noncash Lease Expense
NoncashLeaseExpense
CY2019Q1 dmac Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
CY2018Q1 dmac Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5840000
CY2019Q1 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
796000
CY2018Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
622000
CY2019Q1 dmac Working Capital
WorkingCapital
13500000
CY2018Q4 us-gaap Assets
Assets
18339000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
14944000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
17972000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63123000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62993000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
130000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153000
CY2019Q1 us-gaap Assets
Assets
15494000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
685000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
483000
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
929000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
780000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
686000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
808000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30000
CY2019Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
550000
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
367000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2759000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16823000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1353000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6710000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14064000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5357000
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1591481
CY2019Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11956874
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11956874
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11956874
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11956874
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3249000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-650000
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">redit </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">isk</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company maintains its cash balances primarily with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> financial institutions. These balances exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses in such accounts and believes it is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exposed to any significant credit risk in cash and cash equivalents.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</div></div></div></div></div></div>
CY2019Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
271000
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
271000
CY2019Q1 us-gaap Depreciation
Depreciation
6000
CY2018Q1 us-gaap Depreciation
Depreciation
4000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
365000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
417000
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
39000
CY2019Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000
CY2018Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000
CY2019Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17000
CY2018Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18000
CY2019Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000
CY2018Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
814000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
515000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3243000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-649000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2019Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
86000
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
134000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
201000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-30000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
150000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
709000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-127000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
245000
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-72000
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-13000
CY2019Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
26000
CY2018Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
228000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
46000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
68000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
66000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
48000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
33000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15494000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18339000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1425000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1296000
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
163000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2019Q1 us-gaap Marketable Securities
MarketableSecurities
11000000
CY2019Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10958000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6324000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10928000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3134000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-935000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3252000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-650000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
178000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
657000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
3421000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1306000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3421000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1306000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
16000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
195000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
49000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
CY2019Q1 us-gaap Other Receivables
OtherReceivables
47000
CY2018Q4 us-gaap Other Receivables
OtherReceivables
24000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10928000
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
298000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
369000
CY2019Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
484000
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
120000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
120000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
96000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2607000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
791000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49220000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45968000
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
13000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11956874
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6546780
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
130000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
153000
CY2019Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
430091
CY2019Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
674045
CY2019Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y109D
CY2019Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.77
CY2019Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y255D
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
13906000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
17025000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
6748000

Files In Submission

Name View Source Status
0001437749-19-009677-index-headers.html Edgar Link pending
0001437749-19-009677-index.html Edgar Link pending
0001437749-19-009677.txt Edgar Link pending
0001437749-19-009677-xbrl.zip Edgar Link pending
dmac-20190331.xml Edgar Link completed
dmac-20190331.xsd Edgar Link pending
dmac-20190331_cal.xml Edgar Link unprocessable
dmac-20190331_def.xml Edgar Link unprocessable
dmac-20190331_lab.xml Edgar Link unprocessable
dmac-20190331_pre.xml Edgar Link unprocessable
dmtp20190331_10q.htm Edgar Link pending
ex_143687.htm Edgar Link pending
ex_143688.htm Edgar Link pending
ex_143689.htm Edgar Link pending
ex_143690.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending